News

This multi-center, multi-national study is designed to assess the effectiveness of Mylinax (a proprietary oral formulation of cladribine) in patients with relapsing forms of multiple sclerosis. Endpoints will

The trial, named VISTA, will evaluate Velcade (bortezomib) in combination with melphalan and prednisone versus melphalan and prednisone in patients with newly diagnosed multiple myeloma (MM) who are

In the small safety and immunogenicity study, there was a 36% reduction in median time from administration of the drug to hospital discharge in the Altastaph-treated patients, as

Chugai will use Xencor’s XmAb technology on its antibodies against a cancer target. The XmAb technology consists of a suite of engineered antibody Fc domains that can be

The collaboration between Exelixis and GlaxoSmithKline was established in October 2002 to discover and develop novel therapeutics in the areas of vascular biology, inflammatory disease and oncology. Under

TRU-015 is designed to deplete B lymphocytes and is the first small modular immunopharmaceutical (SMIP) to enter a phase I study. SMIP product candidates utilize key structures –

The project is headed by DVC, the prime systems contractor for the Department of Defense Joint Vaccine Acquisition Program (JVAP), with ID Biomedical serving as the manufacturing development

Under the terms of the agreement, Ortho-McNeil Pharmaceutical will license several lead series of compounds identified by Amphora that are focused on a widely recognized inflammation target for

Rotarix is an oral, two-dose, live attenuated vaccine against rotavirus disease in infants that was licensed in 1997 by Avant Immunotherapeutics to GSK for worldwide commercialization. Rotavirus infection